Purpose: To assess the approach of specialists to ocular tuberculosis (TB). Methods: The American Uveitis Society (AUS) Listserv was surveyed using two clinical cases and general questions. Results: Of 196 members, 87 responded (44.4%), of whom 64 were affiliated with practices in North America, while 23 were outside of North America. The survey provided normative data on how physicians evaluate patients with uveitis as well as opinions about ocular TB. Responses varied widely on such issues as (1) the pretest probability that a patient with granulomatous panuveitis had TB uveitis (range 1-75%) or that a patient with a risk factor for TB had ocular TB (range 0-90%); (2) the optimal duration of anti-TB therapy; and (3) whether therapy should be discontinued after 2 months in nonresponders. Conclusions: Consensus is lacking among uveitis specialists for the diagnosis or management of ocular TB.
Bibliographical noteFunding Information:
See financial disclosures in Conflict of Interest form for Dr. James T. Rosenbaum This research was supported by Research to Prevent Blindness, National Eye Institute core facility grant P30EY010572, the William and Mary Bauman Foundation, and the Stan and Madelle Rosenfeld Family Trust. The Oregon Clinical and Translational Research Institute (OCTRI) also supported this publication: grant number (UL1TR000128) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
© Informa Healthcare USA, Inc.
- Post-test probability
- Pretest probability